QUOTE AND NEWS
Jutia Group  May 18  Comment 
[PR Newswire] - TARRYTOWN, N.Y. and PARIS, May 18, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with...
Benzinga  May 15  Comment 
In a report published Friday, Credit Suisse analysts maintained an Outperform rating on Regeneron Pharmaceuticals Inc (NASDAQ: REGN), while raising the price target from $400 to $550. The analysts believe that the company is "still a strong...
Market Intelligence Center  May 12  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on Regeneron Pharmaceuticals Inc (REGN) could yield about 7.23% (26.14% annualized, for comparison purposes only) in 101 days. Pair a long position in the stock with...
Jutia Group  May 7  Comment 
[PR Newswire] - TARRYTOWN, N.Y., May 7, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced financial results for the first quarter of 2015 and provided an update on development programs. ... Read more on this. ...
Benzinga  May 6  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its first quarter financial results on Thursday, and both the crowd and experts expect to see some growth, although the Street is slightly more bullish. According to...
Forbes  May 6  Comment 
Wall Street is expecting higher profit for Regeneron Pharmaceuticals when the company reports its first quarter results on Thursday, May 7, 2015. The consensus estimate is calling for profit of $2.50 a share, a rise from $1.57 per share a year...
Jutia Group  Apr 29  Comment 
[PR Newswire] - TARRYTOWN, N.Y., April 29, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management presentations at the following investor conferences: Bank of America Merrill Lynch ... Read more on this. ...
Market Intelligence Center  Apr 24  Comment 
Regeneron Pharmaceuticals Inc (REGN) traded between $475.07 and $482.00 before closing at $480.08 Thursday and presents some attractive trading opportunities today according to MarketIntelligenceCenter.com's patented algorithms. The computer...
Jutia Group  Apr 10  Comment 
[PR Newswire] - TARRYTOWN, N.Y., April 10, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on Thursday, May ... Read more on this. ...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki